Strategic partnerships TheracosBio has pursued multiple partnerships to expand access and financial viability for Brenzavvy, including a 2025 nationwide distribution collaboration and a 2026 agreement with OneroRx to reduce patient costs. Leverage these collaboration patterns to propose co-marketing, patient access programs, or payer-agnostic discounting with potential distributors.

AFFORDABLE ACCESS The company emphasizes affordable diabetes therapy through Brenzavvy, including low-cost access initiatives with partners. Identify payers, ACOs, and community clinics focused on cost-effective SGLT2 inhibitors to position Brenzavvy as a preferred, budget-conscious option.

FDA Approved Brenzavvy (bexagliflozin) is FDA-approved, with a commercial launch in 2023 and ongoing expansion efforts. Target pharma distributors, specialty pharmacies, and hospital procurement teams seeking an approved SGLT2 inhibitor with established regulatory credibility.

Regional focus Headquartered in Framingham, MA, TheracosBio is positioned in a robust Northeastern life sciences ecosystem. Prioritize regional stakeholders—Massachusetts-based healthcare systems, Medicaid/Blue Cross plans, and New England specialty distributors—for faster onboarding and pilot programs.

Growth financing Past royalty financing and growth-oriented funding signals a readiness to scale. Propose value-added financing options, volume-based discounts, and collaboration on market access initiatives that align with their expansion timeline and revenue targets.